Drug Trial Radar · NCT02416167
Study of FYU-981 in Hyperuricemia With or Without Gout
Last checked: Nov 19, 2026Latest source record: Feb 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Planned (sponsor's estimate)
Start
May 2015
Primary completion
May 2016
Study completion Nov 2016
Sponsor
- Lead sponsor
- Fuji Yakuhin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 14, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is confirmatory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 12 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 8 weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel group comparison.
Conditions
- Hyperuricemia
Interventions
FYU-981Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent reduction from baseline in serum urate level at the final visitTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Japan
Tokyo and Other Japanese City, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.